Abstract: The present invention provides a method for preventing or treating a liver disease selected from the group consisting of non-alcoholic fatty liver, non-alcoholic steatohepatitis and hepatic fibrosis comprising administrating at least one selected from the group consisting of an Ssu72 peptide, a polynucleotide encoding the Ssu72 peptide, and an expression vector comprising the polynucleotide.

Abstract: The present invention provides a method for preventing or treating a liver disease selected from the group consisting of non-alcoholic fatty liver, non-alcoholic steatohepatitis and hepatic fibrosis comprising administrating at least one selected from the group consisting of an Ssu72 peptide, a polynucleotide encoding the Ssu72 peptide, and an expression vector comprising the polynucleotide.

Abstract: Provided is a vector capable of co-expressing two different target proteins on the microbial surface using two promoters derived from Lactobacillus, and a method of expressing target proteins on the microbial surface using the vector. The vector containing foreign genes inserted therein is transformed into a microorganism, and allows different foreign proteins to be stably expressed on the surface of the microorganism. Furthermore, provided is a surface expression vector containing the gene pgsA encoding a poly-gamma-glutamate synthetase complex, and a method of expressing a target protein on the microbial surface using the vector. The vector containing foreign genes inserted therein is transformed into a microorganism, and allows the foreign proteins to be stably expressed on the surface of the microorganism.

Abstract: The present invention provides a method for preventing or treating a liver disease selected from the group consisting of non-alcoholic fatty liver, non-alcoholic steatohepatitis and hepatic fibrosis comprising administrating at least one selected from the group consisting of an Ssu72 peptide, a polynucleotide encoding the Ssu72 peptide, and an expression vector comprising the polynucleotide.

Abstract: Provided is a surface expression vector having pgsA, a gene encoding poly-gamma-glutamate synthetase, and a method of expressing a target protein on the microbial surface using the vector. The vector having foreign genes inserted therein is transformed into a microorganism and allows a foreign protein to be stably expressed on the surface of the microorganism.

Abstract: Provided is a galactose mutarotase gene promoter derived from Lactobacillus casei and the use thereof, and more particularly, to a Lactobacillus casei-derived galactose mutarotase gene promoter having the nucleotide sequence of SEQ ID NO: 1, an expression vector containing the promoter, and a microorganism transformed with the expression vector. A microorganism transformed with an expression vector containing the promoter may effectively express a target protein on the cell surface, and thus is useful as a vaccine vehicle or the like. Moreover, provided is a surface expression vector having pgsA, which is a gene encoding poly-gamma-glutamate synthetase, and a method of expressing a target protein on the microbial surface using the vector. The vector containing foreign genes inserted therein is transformed into a microorganism and allows a foreign protein is to be stably expressed on the surface of the microorganism.

Abstract: Provided is a pharmaceutical composition for preventing or treating cancer, and more particularly, a pharmaceutical composition for preventing or treating cancer, including dendritic cells with a knock-down Dab2 gene. The composition includes a dendritic cell in which a Dab2 gene is knocked down or knocked out or activity of a Dab2 protein is suppressed as an active ingredient, and thus is expected to be useful as a pharmaceutical composition to prevent, improve or treat cancer as a result of having improved antigen uptake, a migration ability of a cell to a lymph node, and expression of inflammatory cytokines, and activating antigen-specific cytotoxic T cell lymphocyte (CTL) and related T cells that can attack cancer cells, and therefore is expected to be used as the pharmaceutical composition for preventing, improving or treating cancer.

Abstract: Provided is a pharmaceutical composition for preventing or treating cancer, and more particularly, a pharmaceutical composition for preventing or treating cancer, including dendritic cells with a knock-down Dab2 gene. The composition includes a dendritic cell in which a Dab2 gene is knocked down or knocked out or activity of a Dab2 protein is suppressed as an active ingredient, and thus is expected to be useful as a pharmaceutical composition to prevent, improve or treat cancer as a result of having improved antigen uptake, a migration ability of a cell to a lymph node, and expression of inflammatory cytokines, and activating antigen-specific cytotoxic T cell lymphocyte (CTL) and related T cells that can attack cancer cells, and therefore is expected to be used as the pharmaceutical composition for preventing, improving or treating cancer.